China Alendronate Sodium Market Report 2015-2019
DUBLIN, Sep. 04, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/3lrgp9/investigation) has announced the addition of the "Investigation Report on China's Alendronate Sodium Market, 2010-2019" report to their offering.
Alendronate sodium is one of the osteoporosis drugs with the longest history of application. And it is the first diphosphonate that got the FDA's approval to be used for the treatment of postmenopausal osteoporosis and the first drug approved by the FDA to treat osteoporosis in men.
By various mechanisms of action, alendronate sodium can enhance bone strength, alleviate and prevent osteoporosis, effectively reduce the risk of fracture in centrum, hip bone and other parts. It is also the only drug that can effectively reduce the risk in various parts of the body especially in the hip.
Alendronate sodium developed fast after entering China, with annual sales value rising from less than CNY 30 million in 2005 to CNY 121 million in 2014 and CAGR during this period reaching 18.14%. Merck Sharp & Dohme (Italy), CSPC Ouyi Pharmaceutical Co., Ltd, Beijing Wansheng Pharmaceutical Co., Ltd, Haini Pharmaceutical Co., Ltd and Chengdu Tiantaishan Pharmaceutical Co., Ltd occupy the majority of market shares, among of which Merck Sharp & Dohme (Italy) has the largest market share of nearly 90% for sales value in 2014.
The ageing population in China keeps growing, people aged 60 and above amounting to 212.42 million and occupying 15.5% of the total population while people aged 65 and above amounting to 137.55 million and occupying 10.1% of the total population by the end of 2014. With the ageing population, the incidence and number of cases of osteoporosis will continue to grow. Therefore the market size of alendronate sodium is expected to keep expanding in the next few years in China.
Key Topics Covered:
1 Related Concepts of Alendronate Sodium
2 Market Profile of Alendronate Sodium in China
3 Survey on Sales Status of Alendronate Sodium in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Alendronate Sodium in China, 2010-2014
5 Survey on Dosage Forms of Alendronate Sodium in China, 2010-2014
6 Rreference Price of Alendronate Sodium in Chinese Hospitals in 2014
7 Major Manufacturers of Alendronate Sodium in Chinese Market, 2010-2014
8 Market Outlook of Alendronate Sodium in China, 2015-2019
Companies Mentioned
- Haini Pharmaceutical Co., Ltd
- CSPC Ouyi Pharmaceutical Co., Ltd
- Beijing Wansheng Pharmaceutical Co., Ltd
- Chengdu Tiantaishan Pharmaceutical Co., Ltd
- Merck Sharp & Dohme
For more information visit http://www.researchandmarkets.com/research/3lrgp9/investigation
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article